Overcoming Ovarian Cancer Chemoresistance

Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field

Overcoming Drug Resistance in Gynecologic Cancers provides up-to-date information related to important gynecologic cancers and focuses on mechanisms of drug resistance, genetics, signaling, immunology, health disparities, nanotechnology, economic considerations and financial impacts. The book covers not only drug resistance but also important means to reverse resistance both in the laboratory and clinic. The book discusses topics such as lifestyle, nutrition and risk of gynecologic cancers, the financial impact of drug resistance, chemosensitizing agents and targeted therapies in cervical, endometrial and ovarian cancer, immunotherapy to overcome drug resistance, and genetic polymorphisms in gynecologic cancers. Additionally, it discusses ethnic and racial health disparity perspectives and future developments in chemosensitizing activities to reverse drug resistance in gynecologic cancers. It is a valuable resource for cancer researchers, oncologists, clinicians and other biomedical field members who are interested in new approaches to improve chemotherapy outcome in patients with gynecologic cancers. Provides a comprehensive resource with all the details needed for readers to understand and follow information Encompasses schematics, diagrams and flow charts in all chapters to help readers easily follow critical information Presents tables and figures especially developed to summarize the information with appropriate statistical rigor and to show details of clinical specimens such as pathological, radiological characteristics, and/or laboratory biomarkers

Epigenetic Regulation in Overcoming Chemoresistance, Volume 19, explains how epigenetic agents can enhance the chemotherapy sensitivity of diverse types of cancers. The book provides a comprehensive delineation and the recent development of the scientific studies on the epigenetic regulation in enhancing chemo-sensitivity. In addition, it discusses several topics such as DNA methyltransferase inhibitors (DNMTi), Histone deacetylases inhibitors (HDACi), Histone lysine demethylases inhibitors (HDMi), Histone lysine methyltransferases inhibitors (HMTi) and drugs regulating the microRNA, long non-coding RNA (lncRNA) or RNA methylation. Finally, recent and future developments of the field of epigenetic regulation are explored. This is a valuable resource for cancer researchers, clinicians, graduate students and several members of biomedical field who are interested in learning about epigenetic regulation methods to reverse chemo-resistance in cancers. Presents detailed diagrams of the mechanisms of epigenetic regulation for easy consult Encompasses multiple clinical trial summary diagrams to help readers quickly and clearly get information from clinical trials Provides future perspectives in each section to inspire readers to use epigenetic regulation to overcome chemo-resistance

Offers women with ovarian cancer support and resources to help them deal with the physical and emotional impact of their disease.

Despite the significant advances in cancer therapy made through constant evaluation and analysis of treatment aftereffects, the disease still remains one of the foremost causes of mortality worldwide killing more than 12 million people annually. The prime reason behind the failure of conventional chemotherapeutics which are used as the chief regimen in the comprehensive treatment of cancers is the development of chemoresistance. It can be either intrinsic or acquired and is primarily mediated via different key regulators like MDR, MAPK, NF-κB, PI3K/Akt, Wnt signaling pathways etc. Thus, agents which can target these regulatory elements or pathways and in turn sensitize cancer cells to chemotherapy holds immense prospect. However, there is barely such comprehensive work available in scientific literature that explains how chemosensitization of cancer cells functions using different drug combinations and exhibit synergism. This book provides a detailed description of chemoresistance and chemosensitization, targets for chemosensitization and various approaches adapted in the process of chemosensitization. Furthermore, the book explicates the role of various chemosensitizers, both natural and synthetic in sensitizing cancer cells and also details the current research findings on chemosensitization of different cancer types in both pre-clinical and clinical settings. Contents: Introduction and Basic Concepts of Cancer (Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Nafiseh Manteghi, Ganesan Padmavathi and Ajaikumar B Kunnumakkara ) Cancer Cell Chemoresistance: A Prime Obstacle in Cancer Therapy (Javadi Monisha, Aviral Jaiswal, Kishore Banik, Harsha Choudhary, Anuj Kumar Singh, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Bladder Cancer: Chemoresistance and Chemosensitization (Nand Kishor Roy, Anand Sharma, Anuj Kumar Singh, Devivasha Bordoloi, Bethsebie Lalduhsaki Sailo, Javadi Monisha and Ajaikumar B Kunnumakkara) Mechanism of Chemoresistance in Bone Cancer and Different Chemosensitization Approaches (Ganesan Padmavathi, Devivasha Bordoloi, Kishore Banik, Javadi Monisha, Anuj Kumar Singh and Ajaikumar B Kunnumakkara) Chemoresistance in Brain Cancer and Different Chemosensitization Approaches (Amrita Devi Khwairakpam, Javadi Monisha, Kishore Banik, Harsha Choudhary, Anand Sharma, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Phytochemicals as Chemosensitizers in Breast Cancer (Madhumita Roy, Ruma Sarkar, Apurba Mukherjee, Sutapa Mukherjee and Jaydip Biswas) Potential of Different Chemosensitizers to Overcome Chemoresistance in Cervical Cancer (Kishore Banik, Bethsebie Lalduhsaki Sailo, Krishan Kumar Thakur, Aviral Jaiswal, Javadi Monisha, Devivasha Bordoloi and Ajaikumar B. Kunnumakkara) Colon Cancer Chemoresistance and Chemosensitization (Muthu K Shanmugam, Arunasalam Dharmarajan, Frank Arfuso and Gautam Sethi) Cancer Cell Chemoresistance and Chemosensitization in Endometrial Cancer (Anuj Kumar Singh, Javadi Monisha, Kishore Banik, Harsha Choudhary, Amrita Devi Khwairakpam, Devivasha Bordoloi and Ajaikumar B Kunnumakkara) Different Approaches to Overcome Chemoresistance in Esophageal Cancer (Devivasha Bordoloi, Kishore Banik, Amrita Devi Khwairakpam, Anand Sharma, Javadi Monisha, Bethsebie Lalduhsaki Sailo and Ajaikumar B Kunnumakkara) Different Chemosensitization Approaches in Gastric Cancer (Harsha Choudhary, Devivasha Bordoloi, Jai Prakash, Nafiseh Manteghi, Ganesan Padmavathi, Javadi Monisha and Ajaikumar B Kunnumakkara) Chemoresistance and Chemosensitization in Hematological Malignancies (Ota Fuchs) Different Methods to Inhibit Chemoresistance in Hepatocellular Carcinoma (Anuj Kumar Singh, Nand Kishor Roy, Anand Anip, Kishore Banik, Javadi Monisha, Devivasha Bordoloi

Over the past 50 years many in vitro and in vivo drug response assay systems have been developed to determine the potential - tivity of chemotherapy agents. The idea was to eliminate ineffective agents and unnecessary toxic treatment while selecting drugs active in vitro or in the mouse model that might increase the probability of response in the patient. None of these test models, however, achieved routine clinical application in the past. This might be at least in part - lated to large discrepancies that were described between the s- cess rate of the assay systems and the clinical benefit in cancer - tients. The heterogeneity of chemosensitivity that exists between different tumors as well as between individual tumor lesions may be one explanation for these findings. Furthermore, different assay end points such as proliferation, metabolism, and vitality were - veloped to evaluate the effects of cytostatic drugs on tumor cells, and these might be related to the differing results. However, knowledge about procedures for assay-assisted treatment selection has increased rapidly within the past few years, and several studies suggest that test-directed chemotherapy selection now may - prove response rates and survival in various types of tumors. The International Society for Chemosensitivity Testing in - cology (ISCO) was founded to promote, coordinate, and improve clinical and laboratory research in the field of predictive drug te- ing in human tumor cells.

Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.

Strategies for overcoming chemotherapy resistance in cervical cancer highlights different strategies to reverse chemotherapy resistance in cervical cancer. The book has a strong focus on strategies to reverse chemotherapy resistance as well as strategies for early detection of the resistance, enhancing precision oncology in terms of patient care and maximizing patient management. The book also looks at virally induced resistance to chemotherapy and recommends combination therapies that can maximize the reversal of this resistance. In 10 chapters Strategies for overcoming chemotherapy resistance in cervical cancer not only gives an overview of cervical cancer and chemotherapy as treatment, but it also investigates resistance to chemotherapy and the treatment for resistance. It defines the treatment mechanisms, options, and limitations to beat chemotherapy resistance and the reversal of the resistance mechanisms. It gives insights into the future directions of cervical cancer treatment using epigenetic silencing, chemotherapy splicing, the involvement of MicroRNAs to chemotherapy resistance, and the application of Artificial Intelligence. This book is a valuable resource for health professionals, scientists and researchers, oncologists, virologists, health practitioners, medical and graduate students, and all those who wish to broaden their knowledge in the allied field. Discusses strategies to reverse and detect resistance to chemotherapy at an early stage Investigates the applications of Artificial Intelligence in the study of cervical chemotherapy resistance Presents research and applications developed to overcome cancer resistance